The EPS miss and accelerating cash burn are near-term headwinds, but the mid-2026 Seabreeze STAT data readout is the primary catalyst. Monitor for any pre-data financing needs — the $46M runway is tight for a Phase 2 biotech.
Price Chart
Executive Summary
Connect Biopharma reported Q1 2026 net loss of $0.34 per share, significantly wider than the consensus estimate of -$0.28, driven by a 127% surge in R&D costs as the Phase 2 Seabreeze STAT studies ramp up. The company maintains a $46M cash runway into H2 2027 and expects topline data from both asthma/COPD studies mid-2026, but the EPS miss and escalating burn rate overshadow the clinical progress.
Key Financial Metrics
Key Facts
- Q1 2026 net loss per share of ($0.34) vs consensus ($0.28) — a 21.4% miss
- Net loss widened to $19.4M from $10.3M YoY, driven by R&D expense increase to $15.0M from $6.6M
- Cash and equivalents of $46.0M as of March 31, 2026, sufficient into H2 2027
- Phase 2 Seabreeze STAT asthma/COPD studies on track for topline data mid-2026
- Closed $20.2M private placement on March 31, 2026, with estimated net proceeds of $18.6M
- License revenue of $0.2M from Simcere partnership; eligible for up to ~$110M in milestones
Financial Impact
EPS miss of 21.4% vs consensus; net loss increased 89% YoY to $19.4M
Risk Factors
- Cash burn rate increased sharply; may require additional financing before data readout
- Phase 2 Seabreeze STAT studies may fail to meet endpoints, given early-stage nature
- No approved products or recurring revenue; fully dependent on clinical trial success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292887 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | SC 13G | $0.9450 $0.9090 | ▼ −3.81% | ▼ −2.83% | $0.8425 (−10.85%) |
Sep 30, 2026 27d ago | 8-K | $1.10 $0.9450 | ▼ −14.09% | ▼ −16.00% | $0.8425 (−23.41%) |
Sep 30, 2026 27d ago | Press Release | $1.10 $0.9447 | ▼ −14.12% | ▼ −16.03% | $0.8425 (−23.41%) |
Sep 15, 2026 6w ago | 8-K | $1.17 $1.28 | ▲ +9.40% | ▲ +8.58% | $0.8425 (−27.99%) |
May 12, 2026 24w ago | 8-K | $2.68 $2.38 | ▼ −11.19% | ▼ −11.27% | $0.8425 (−68.56%) |
May 12, 2026 24w ago | Press Release | $2.68 $2.38 | ▲ +11.19% | ▲ +11.27% | $0.8425 (+68.56%) |
Apr 23, 2026 26w ago | 8-K | $2.52 $2.53 | ▲ +0.40% | ▼ −1.08% | $0.8425 (−66.57%) |
Mar 31, 2026 30w ago | 8-K | $2.72 $2.78 | ▲ +2.21% | ▼ −1.56% | $0.8425 (−69.03%) |
Mar 30, 2026 30w ago | Press Release | $2.90 $2.82 | ▼ −2.76% | ▼ −7.06% | $0.8425 (−70.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers